By Dr Louise Emmett

Journal articles

Kratochwil C; Fendler WP; Eiber M; Hofman MS; Emmett L; Calais J; Osborne JR; Iravani A; Koo P; Lindenberg L; Baum RP; Bozkurt MF; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen WJG; Rahbar K; Schoder H; Virgolini I; Bodei L; Fanti S; Haberkorn U; Hermann K, 2023, 'Joint EANM/SNMMI procedure guideline for the use of ¹⁷⁷Lu-labeled PSMA-targeted radioligand-therapy (¹⁷⁷Lu-PSMA-RLT)', European Journal of Nuclear Medicine and Molecular Imaging, 50, pp. 2830 - 2845, http://dx.doi.org/10.1007/s00259-023-06255-8

Solomonidou N; Germanou D; Strouthos I; Karagiannis E; Farolfi A; Koerber SA; Debus J; Peeken JC; Vogel ME; Vrachimis A; Spohn SKB; Shelan M; Aebersold D; Grosu AL; Ceci F; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Hruby G; Scharl S; Wiegel T; Bartenstein P; Henkenberens C; Emmett L; Schmidt-Hegemann NS; Ferentinos K; Zamboglou C, 2023, 'PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml', European Journal of Nuclear Medicine and Molecular Imaging, 50, pp. 2529 - 2536, http://dx.doi.org/10.1007/s00259-023-06185-5

Scharl S; Zamboglou C; Strouthos I; Farolfi A; Serani F; Lanzafame H; Giuseppe Morganti A; Trapp C; Koerber SA; Debus J; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Ruf J; Grosu AL; Ceci F; Fendler WP; Bartenstein P; Kroeze SGC; Guckenberger M; Krafcsik M; Klopscheck C; Fanti S; Hruby G; Emmett L; Belka C; Stief C; Schmidt-Hegemann NS; Henkenberens C; Mayer B; Miksch J; Shelan M; Aebersold DM; Thamm R; Wiegel T, 2023, 'Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study', Radiotherapy and Oncology, 184, http://dx.doi.org/10.1016/j.radonc.2023.109678

Lengyelova E; Wong V; Lenzo N; Parker M; Emmett L, 2023, '⁶⁴Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer.', Journal of Clinical Oncology, 41, pp. 5039 - 5039, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5039

Hamid A; Gupta S; Keerthikumar S; Pasam A; Crumbaker M; Joshua AM; Lam E; Wenstrup R; Emmett L; Goode DL; Hofman MS; Sandhu S, 2023, 'Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus ¹⁷⁷lutetium-prostate specific membrane antigen-617 (¹⁷⁷Lu-PSMA-617) in the LuPARP trial.', Journal of Clinical Oncology, 41, pp. 5064 - 5064, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5064

Unterrainer L; Farolfi A; Rosar F; Denis CS; Emmett L; de Kouchkovsky I; Hope TA; Hotta M; Gafita A; Djaileb L; Czernin J; Calais J, 2023, 'Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study.', Journal of Clinical Oncology, 41, pp. 5063 - 5063, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5063

Soon YY; Marschner I; Hofman MS; Emmett L; Davis ID; Stockler MR; Martin AJ, 2023, 'Effects of [¹⁷⁷Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis.', Journal of Clinical Oncology, 41, pp. 5045 - 5045, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5045

Feldman DR; Tran B; Emmett L; Hofman MS; Olivier P; Mahammedi H; Galetic I; Pokorska-Bocci A; Bouisset F; Gollmer K; Pavlyuk M; Tauchmanova L; Herrmann K, 2023, 'First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors.', Journal of Clinical Oncology, 41, pp. TPS3160 - TPS3160, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps3160

Sandhu S; Joshua AM; Emmett L; Crumbaker M; Bressel M; Huynh R; Banks PD; Wallace R; Hamid A; Inderjeeth AJ; Tran B; Azad A; Alipour R; Kong G; Ravi Kumar A; Saghebi J; Williams S; Akhurst TJ; Hicks RJ; Hofman MS, 2023, 'LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 41, pp. 5005 - 5005, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5005

Zamboglou C; Peeken JC; Janbain A; Katsahian S; Strouthos I; Ferentinos K; Farolfi A; Koerber SA; Debus J; Vogel ME; Combs SE; Vrachimis A; Morganti AG; Spohn SKB; Shelan M; Aebersold DM; Grosu AL; Ceci F; Henkenberens C; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Bartenstein P; Hruby G; Scharl S; Wiegel T; Emmett L; Arnoux A; Schmidt-Hegemann NS, 2023, 'Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer', JAMA network open, 6, pp. e2314748, http://dx.doi.org/10.1001/jamanetworkopen.2023.14748

Seifert R; Emmett L; Rowe SP; Herrmann K; Hadaschik B; Calais J; Giesel FL; Reiter R; Maurer T; Heck M; Gafita A; Morris MJ; Fanti S; Weber WA; Hope TA; Hofman MS; Fendler WP; Eiber M, 2023, 'Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)', European Urology, 83, pp. 405 - 412, http://dx.doi.org/10.1016/j.eururo.2023.02.002

Doan P; Counter W; Papa N; Sheehan-Dare G; Ho B; Lee J; Liu V; Thompson JE; Agrawal S; Roberts MJ; Buteau J; Hofman MS; Moon D; Lawrentschuk N; Murphy D; Stricker PD; Emmett L, 2023, 'Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer', BJU International, 131, pp. 588 - 595, http://dx.doi.org/10.1111/bju.15929

Zamboglou C; Arnoux A; Janbain A; Strouthos I; Farolfi A; Koerber S; Peeken J; Vogel M; Ferentinos K; Shelan M; Grosu AL; Kroeze S; Guckenberger M; Fanti S; Hruby G; Scharl S; Wiegel T; Henkeberens C; Emmett L; Hegemann N-S, 2023, 'Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET–based salvage radiotherapy in recurrent prostate cancer.', Journal of Clinical Oncology, 41, pp. 355 - 355, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.355

Sandhu S; Subramaniam S; Hofman MS; Stockler MR; Martin AJ; Pokorski I; Goh JC; Pattison DA; Dhiantravan N; Gedye C; Rutherford NK; Joshua AM; Tan TH; Kirkwood ID; Lee ST; Weickhardt AJ; Alipour R; Nguyen A; Davis ID; Emmett L, 2023, 'Evolution: Phase II study of radionuclide ¹⁷⁷Lu-PSMA-617 therapy versus ¹⁷⁷Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).', Journal of Clinical Oncology, 41, pp. TPS271 - TPS271, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps271

Tremblay S; Alhogbani M; Weickhardt A; Davis ID; Scott AM; Hicks RJ; Metser U; Chua S; Davda R; Punwani S; Payne HA; Tunariu N; Ho B; Young S; Bauman G; Emmett L; Pouliot F, 2023, 'Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: A post hoc analysis of the PROPS trial.', Journal of Clinical Oncology, 41, pp. 316 - 316, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.316

Gupta S; Hamid A; Fernandez L; Pasam A; Lam E; Tubbs A; Bourdon D; Emmett L; Joshua AM; Hofman MS; Wenstrup R; Sandhu S, 2023, 'Performance of a blood-based liquid biopsy test to detect PSMA expression on circulating tumor cells in men with metastatic prostate cancer.', Journal of Clinical Oncology, 41, pp. 256 - 256, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.256

Emmett L; Wong V; Lenzo N; Lengyelova E; Biggin C, 2023, 'Positron emission tomography of patients with confirmed prostate cancer using ⁶⁴Cu-SAR-bisPSMA.', Journal of Clinical Oncology, 41, pp. 318 - 318, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.318

Buteau JP; Moon D; Fahey MT; Roberts M; Thompson J; Murphy DG; Papa N; Mitchell C; Kasivisvanathan V; Stricker P; O'Brien J; Counter W; Sharma G; Agrawal S; Ho B; Yeung T; De Abreu Lourenço R; Dhillon HM; Hofman MS; Emmett L, 2023, 'PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [⁶⁸Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer.', Journal of Clinical Oncology, 41, pp. TPS397 - TPS397, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps397

Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L, 2023, 'Evaluation of ¹⁷⁷Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective ¹⁷⁷Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398

John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L, 2023, '¹⁷⁷Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing ¹⁷⁷Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677

Horsley PJ; Koo CM; Eade T; Hsiao E; Emmett L; Brown C; Kneebone A; Hruby G, 2023, 'Mapping of Local Recurrences After Radical Prostatectomy Using 68-Gallium–Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: Implications for Postprostatectomy Radiation Therapy Clinical Target Volumes', International Journal of Radiation Oncology Biology Physics, 115, pp. 106 - 117, http://dx.doi.org/10.1016/j.ijrobp.2022.05.044

Emmett L; John N; Pathmanandavel S; Counter W; Ayers M; Sharma S; Agrawal S; Poole A; Hovey E; Pranavan G; Gedye C; Mallesara G; Guminski A; Lee A; Stockler MR; Hickey A; Eu P; Joshua AM; Crumbaker M; Nguyen A, 2023, 'Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)', Therapeutic Advances in Medical Oncology, 15, http://dx.doi.org/10.1177/17588359231156392

Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L, 2023, 'The Prognostic Value of Posttreatment ⁶⁸Ga-PSMA-11 PET/CT and ¹⁸F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with ¹⁷⁷Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104

Roberts MJ; Maurer T; Perera M; Eiber M; Hope TA; Ost P; Siva S; Hofman MS; Murphy DG; Emmett L; Fendler WP, 2023, 'Using PSMA imaging for prognostication in localized and advanced prostate cancer', Nature Reviews Urology, 20, pp. 23 - 47, http://dx.doi.org/10.1038/s41585-022-00670-6

Goode D; Keerthikumar S; Gupta S; Joshua AM; Emmett L; Crumbaker M; Singer T; Lam E; Fernandez L; Jimenez E; Zhang D; Lin Y; Wenstrup RJ; PASAM A; Hicks R; Kong G; Hamid A; Sandhu SK, 2023, '1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', Annals of Oncology, 34, pp. S988 - S989, http://dx.doi.org/10.1016/j.annonc.2023.09.2773

Emmett L; Subramaniam S; Crumbaker M; Joshua AM; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JCH; Pattison DA; Tan H; Kirkwood ID; Sandhu SK; Nguyen A; Gedye C; Rutherford N; Hofman M; Martin A; Stockler MR; Davis ID, 2023, 'LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)', Annals of Oncology, 34, pp. S1325 - S1325, http://dx.doi.org/10.1016/j.annonc.2023.10.086

Zamboglou C; Ferentinos K; Arnoux A; Janbain A; Strouthose I; Farolfi A; Koerber S; Peeken J; Vogel M; Vrachimis A; Spohn SKB; Shelan M; Grosu A; Kroeze S; Guckenberger M; Fanti SF; Belka C; Hruby G; Scharl S; Wiegel T; Henkenberens C; Emmett L; Schmidt-Hegemann NS, 2023, 'OC-0435 Multi-institutional nomogram for PSMA-PET based salvage radiotherapy in recurrent prostate cancer', Radiotherapy and Oncology, 182, pp. S335 - S336, http://dx.doi.org/10.1016/s0167-8140(23)08607-3

Scheltema MJV; Geboers B; Meijer D; Counter W; Thompson J; Doan P; Gondoputro W; Katelaris A; Haynes AM; Delprado W; Vis A; van Leeuwen P; Ho B; Liu V; Lee J; Donswijk M; Oprea-Lager D; Emmett L; Stricker P, 2023, 'The value of PSMA-PET in Addition to mpMRI and Systematic Biopsies to Select Patients for Hemi-ablative Focal Therapy in Prostate Cancer', European Urology Open Science, 57, pp. S45 - S45, http://dx.doi.org/10.1016/s2666-1683(23)01325-3

van Leeuwen PJ; Emmett L, 2022, '¹⁸F-PSMA-11 as an Attractive ⁶⁸Ga-PSMA-11 Alternative for Prostate Cancer Imaging', European Urology, 82, pp. 510 - 511, http://dx.doi.org/10.1016/j.eururo.2022.06.001

Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L, 2022, 'Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups', BJU International, 130, pp. 32 - 39, http://dx.doi.org/10.1111/bju.15762

Ptasznik G; Papa N; Kelly BD; Thompson J; Stricker P; Roberts MJ; Hofman MS; Buteau J; Murphy DG; Emmett L; Moon D, 2022, 'High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer', BJU International, 130, pp. 5 - 7, http://dx.doi.org/10.1111/bju.15736

Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee ST; Azad AA; McJannett MM; Stockler MR; Williams SG; Davis ID; Hofman MS; Akhurst T; Alipour R; Banks P; Beaulieu A; Chua W; Dhiantravan N; Ford K; Gedye C; Goh JC; Guminski A; Hamid A; Haskali MB; Hicks RJ; Hsiao E; Kirkwood ID; Kong G; Kwan EM; Langford A; Lawrence N; Lewin J; Lin P; McDonald W; Moodie K; Murphy DG; Ng S; Pattison DA; Pokorski I; Ramdave S; Ravi Kumar AS; Redfern AD; Rutherford NK; Saghebi J; Spain L; Subramaniam S; Tan TH; Thang SP; Tran B; Wallace R; Weickhardt A; Yip S, 2022, 'PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial', The Lancet Oncology, 23, pp. 1389 - 1397, http://dx.doi.org/10.1016/S1470-2045(22)00605-2

Emmett L; Papa N; Buteau J; Ho B; Liu V; Roberts M; Thompson J; Moon D; Sheehan-Dare G; Alghazo O; Agrawal S; Murphy D; Stricker P; Hope TA; Hofman MS, 2022, 'The PRIMARY Score: Using Intraprostatic ⁶⁸Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63, pp. 1644 - 1650, http://dx.doi.org/10.2967/jnumed.121.263448

Fanti S; Briganti A; Emmett L; Fizazi K; Gillessen S; Goffin K; Hadaschik BA; Herrmann K; Kunikowska J; Maurer T; MacLennan S; Mottet N; Murphy DG; Oprea-Lager DE; O'Sullivan JM; Oyen WJG; Rouvière O; Sartor O; Stenzl A; Van Poppel H; Walz J; Witjes W; Bjartell A, 2022, 'EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy', European urology oncology, 5, pp. 530 - 536, http://dx.doi.org/10.1016/j.euo.2022.05.003

Pomykala KL; Herrmann K; Emmett L; Lalumera E; Fanti S, 2022, 'Virtual Prostate Biopsy with Prostate-specific Membrane Antigen and Magnetic Resonance Imaging: Closer to Reality in a Subgroup of Prostate Cancer Patients?', European Urology Open Science, 44, pp. 11 - 12, http://dx.doi.org/10.1016/j.euros.2022.07.015

Nguyen A; Fullard K; Sheehan-Dare G; Tang R; Chan L; Ho B; Dear R; Keane J; Hickey A; Nandurkar R; Chen J; Chen A; Lim E; Emmett L, 2022, 'Diagnostic value of ⁶⁸Ga-DOTATATE PET-CT imaging for staging of ER⁺/PR⁺ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and ¹⁸F-FDG PET-CT in a prospective pilot trial', Journal of Medical Imaging and Radiation Oncology, 66, pp. 731 - 737, http://dx.doi.org/10.1111/1754-9485.13342

Wong K; Sheehan-Dare G; Nguyen A; Ho B; Liu V; Lee J; Brown L; Dear R; Chan L; Sharma S; Malaroda A; Smith I; Lim E; Emmett L, 2022, '64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial', Pharmaceuticals, 15, http://dx.doi.org/10.3390/ph15070772

Roberts MJ; Morton A; Papa N; Franklin A; Raveenthiran S; Yaxley WJ; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Emmett L; Yaxley JW, 2022, 'Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy', European Journal of Nuclear Medicine and Molecular Imaging, 49, pp. 3289 - 3294, http://dx.doi.org/10.1007/s00259-022-05756-2

Emmett L; Pattison DA; Roberts MJ, 2022, 'All Prostate-specific Membrane Antigen Peptides Are Equal, but Some Are More Equal than Others', European urology oncology, 5, pp. 283 - 284, http://dx.doi.org/10.1016/j.euo.2022.04.002

Lee ST; Emmett LM; Pattison DA; Hofman MS; Bailey DL; Latter MJ; Francis RJ; Scott AM, 2022, 'The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective', Journal of Nuclear Medicine, 63, pp. 819 - 822, http://dx.doi.org/10.2967/JNUMED.122.263996

Dieng M; Lord SJ; Turner RM; Nieweg OE; Menzies AM; Saw RPM; Einstein AJ; Emmett L; Thompson JF; Lo SN; Morton RL, 2022, 'The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma', Annals of Surgical Oncology, 29, pp. 2871 - 2881, http://dx.doi.org/10.1245/s10434-021-11231-3

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L, 2022, '¹⁷⁷Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566, http://dx.doi.org/10.2967/jnumed.121.262552

Roberts MJ; Emmett L, 2022, 'EDITORIAL COMMENT', Journal of Urology, 207, pp. 348 - 349, http://dx.doi.org/10.1097/JU.0000000000002254.01

Liu W; Fakir H; Randhawa G; Alfano R; Corkum M; Kassam Z; Rachinsky I; Chung HT; Chung P; Loblaw A; Morton G; Sexton T; Kapoor A; Ward A; Zukotynski K; Emmett L; Bauman G, 2022, 'Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRI', Clinical and Translational Radiation Oncology, 32, pp. 41 - 47, http://dx.doi.org/10.1016/j.ctro.2021.11.006

Dimitriou F; Lo SN; Tan AC; Emmett L; Kapoor R; Carlino MS; Long GV; Menzies AM, 2022, 'FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma', Annals of Oncology, 33, pp. 99 - 106, http://dx.doi.org/10.1016/j.annonc.2021.10.003

Hagens MJ; Oprea-Lager DE; Vis AN; Wondergem M; Donswijk ML; Meijer D; Emmett L; van Leeuwen PJ; van der Poel HG, 2022, 'Reproducibility of PSMA PET/CT Imaging for Primary Staging of Treatment-Naïve Prostate Cancer Patients Depends on the Applied Radiotracer: A Retrospective Study', Journal of Nuclear Medicine, 63, pp. 1531 - 1536, http://dx.doi.org/10.2967/jnumed.121.263139

Gondoputro W; Scheltema MJ; Blazevski A; Doan P; Thompson JE; Amin A; Geboers B; Agrawal S; Siriwardana A; Van Leeuwen PJ; van Oosterom MN; Van Leeuwen FWB; Emmett L; Stricker PD, 2022, 'Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer', Journal of Nuclear Medicine, 63, pp. 1659 - 1664, http://dx.doi.org/10.2967/JNUMED.121.263743

Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L, 2021, 'Phase I/II Trial of the Combination of ¹⁷⁷Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European urology oncology, 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002

Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P, 2021, 'The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study[Formula presented]', European Urology, 80, pp. 682 - 689, http://dx.doi.org/10.1016/j.eururo.2021.08.002

Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID, 2021, 'ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)', BJU International, 128, pp. 642 - 651, http://dx.doi.org/10.1111/bju.15491

Back to profile page